25 related articles for article (PubMed ID: 27342662)
1. GSG2 promotes thyroid cancer via stabilizing AURKB and activating AKT pathway.
Zhang F; Huang C
Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
[TBL] [Abstract][Full Text] [Related]
2. MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Liu Y; Xu S; Huang Y; Liu S; Xu Z; Wei M; Liu J
Int J Biol Sci; 2021; 17(13):3401-3412. PubMed ID: 34512155
[TBL] [Abstract][Full Text] [Related]
3. Hsp70 acts as a fine-switch that controls E3 ligase CHIP-mediated TAp63 and ΔNp63 ubiquitination and degradation.
Wu HH; Wang B; Armstrong SR; Abuetabh Y; Leng S; Roa WHY; Atfi A; Marchese A; Wilson B; Sergi C; Flores ER; Eisenstat DD; Leng RP
Nucleic Acids Res; 2021 Mar; 49(5):2740-2758. PubMed ID: 33619536
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer.
Papin S; Paganetti P
Brain Sci; 2020 Nov; 10(11):. PubMed ID: 33207722
[TBL] [Abstract][Full Text] [Related]
5. Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly.
Balaji V; Hoppe T
F1000Res; 2020; 9():. PubMed ID: 32076548
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin ligase CHIP modulates cellular behaviors of gastric cancer cells by regulating TRAF2.
Dai H; Chen H; Xu J; Zhou J; Shan Z; Yang H; Zhou X; Guo F
Cancer Cell Int; 2019; 19():132. PubMed ID: 31130821
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of anlotinib in thyroid cancer.
Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
[TBL] [Abstract][Full Text] [Related]
8. CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin.
Xu J; Zhou J; Dai H; Liu F; Li W; Wang W; Guo F
J Transl Med; 2018 Jun; 16(1):169. PubMed ID: 29921293
[TBL] [Abstract][Full Text] [Related]
9. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
10. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
11. [Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer].
Liu B; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1221-5. PubMed ID: 23469561
[TBL] [Abstract][Full Text] [Related]
12. CHIP promotes thyroid cancer proliferation via activation of the MAPK and AKT pathways.
Zhang L; Liu L; He X; Shen Y; Liu X; Wei J; Yu F; Tian J
Biochem Biophys Res Commun; 2016 Aug; 477(3):356-62. PubMed ID: 27342662
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
Cheng L; Zang J; Dai HJ; Li F; Guo F
Int J Oncol; 2018 Jul; 53(1):203-214. PubMed ID: 29693147
[TBL] [Abstract][Full Text] [Related]
14. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
[TBL] [Abstract][Full Text] [Related]
15. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.
Zhu W; Xue Y; Liang C; Zhang R; Zhang Z; Li H; Su D; Liang X; Zhang Y; Huang Q; Liu M; Li L; Li D; Zhao AZ; Liu Y
Tumour Biol; 2016 Sep; 37(9):12241-12250. PubMed ID: 27240591
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
